AbbVie in January paid $105 million for an exclusive option to license small Tizona's experimental cancer-fighting drug, so the results from an early-stage clinical trial started this month are important.
AbbVie in January paid $105 million for an exclusive option to license small Tizona's experimental cancer-fighting drug, so the results from an early-stage clinical trial started this month are important.
